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Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disturbances that 
includes simple steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and 
liver cancer. NAFLD affects individuals that consume the typical Western diet consisting 
of high levels of fats and carbohydrates. The increase in circulating free fatty acids, 
palmitate and oleate, or lipopolysaccharides (LPS), induce oxidative stress and pro-
inflammatory cytokine production in the liver, which all contribute to NAFLD progression. 
In this study, we are evaluating the mRNA expression of genes associated with fatty acid 
oxidation (FAO) and the protein expression of pro-inflammatory cytokines related to 
NAFLD using the HepG2 human liver hepatocellular carcinoma cells exposed to 
palmitate/oleate or LPS. The treatment of sodium butyrate (NaB) or sodium propionate 
(NaP) was used to relieve oxidative stress and inflammation in liver cells. The quantitative 
real-time polymerase chain reaction (qRT-PCR) results show that NaP or NaB, were able 
to promote FAO, regulate lipolysis, and reduce reactive oxygen species production by 
significantly increasing the mRNA expression of peroxisome proliferator-activated 
receptor gamma coactivator 1 alpha (PGC-1α), peroxisome proliferator-activated 
receptor alpha (PPARα), adipose triglyceride lipase (ATGL), carnitine 
palmitoyltransferase 1 alpha (CPT1α), fibroblast growth factor 21 (FGF21), and 
uncoupling protein 2 (UCP2) in HepG2 cells. Together, NaP and NaB may produce 
synergistic effects by significantly increasing CPT1α, PPARα, and UCP2 mRNA 
expression in LPS-induced HepG2 cells and by significantly increasing CPT1α and ATGL 




have the ability to reverse hepatic steatosis and increase whole-body energy expenditure 
by significantly increasing FGF21 mRNA expression in palmitate/oleate-induced HepG2 
cells. The ELISA results reveal that only LPS significantly increased Tumor Necrosis 
Factor alpha (TNF-α) expression in HepG2 cells. At the same time, NaP alone or in 
combination with NaB significantly decreased TNF-α expression in LPS-induced HepG2 
cells. The expression of IL-8 in both models showed no significant differences in all 
treatments. The Western blot analysis of CPT1α protein expression increased by NaP 
alone or in combination with NaB in the palmitate/oleate model. In conclusion, this study 












CHAPTER 1. LITERATURE REVIEW 
1.1. Non-Alcoholic Fatty Liver Disease Overview  
The Western diet often consists of the high consumption of fats and carbohydrates, 
which leads to a caloric surplus and multiple metabolic diseases such as non-alcoholic 
fatty liver disease (NAFLD). This disease is the accumulation of fat build up in the liver 
with little to no consumption of alcohol and is the most common chronic liver disease 
around the world [1]. The liver is a multifunctional organ and is a principal regulator of 
lipids in the body [2]. However, when the liver’s weight is 5-10% fat, it is considered a fatty 
liver which causes the increase of free fatty acids, oxidative stress, and subsequently 
inflammation and fibrosis. NAFLD affects around 35% of the general population and 76%-
90% of disease-specific groups, such as obesity and diabetes [1]. The rising prevalence 
of NAFLD has made it the second most common cause of liver transplantation in the 
United States [3]. NAFLD is strongly associated with obesity, cardiovascular disease 
(CVD), including coronary heart disease and stroke, and metabolic syndrome, including 
insulin resistance, type 2 diabetes mellitus, hypertension, and dyslipidemia [4]. The 
continuum of NAFLD starts as fat accumulation in the liver, then inflammation and 
scarring that leads to non-alcoholic steatohepatitis (NASH), and lastly, cirrhosis occurs in 
which scar tissue replaces the liver cells.  
The prevalence of NAFLD is difficult to diagnosis since patients are usually 
asymptomatic until they develop cirrhosis [5]. The diagnosis is often due to incidental 
elevations of serum alanine transaminase (ALT) and aspartate aminotransferase (AST) 
[5]. The gold standard for quantitating the stages of NAFLD is liver biopsy but can be 




pathologic classifications of NAFLD are Matteoni’s, Brunt’s, Kleiner’s classification with 
the NAFLD Activity Score (NAS), Fatty Liver Inhibition of Progression (FLIP) algorithm 
with Steatosis Activity, and Fibrosis (SAF) Score [6]. Currently, NAS is the most 
commonly used examination in clinical trials [6]. However, there are many limitations, 
such as high variability among pathologists, poor correlation with metabolic risk factors, 
and the inability to predict fibrosis progression [7, 8]. Imaging methods are the most widely 
used non-invasive techniques for the diagnosis of NAFLD [6]. Ultrasonography is the 
most common method because of its safety, low cost, and ability to detect if a liver has 
more than 30% fat [6]. The main limitation of this method is the inability to differentiate 
steatosis from fibrosis [6].  
1.2. Molecular Mechanisms in Non-Alcoholic Fatty Liver Disease 
The liver is an essential organ in lipid metabolism and a central regulator of lipid 
homeostasis [9]. The liver is responsible for the synthesis of new fatty acids and their 
export and distribution to other tissues, as well as their use as energy substrates [9]. 
These processes are regulated by complex interactions between hormones, nuclear 
receptors, and transcription factors, which keep hepatic lipid homeostasis under control 
[10]. The disturbance of one or more of these pathways may cause the retention of fat 
within the liver, which can cause the development of NAFLD [9]. Hepatic fat build up 
results from an imbalance between lipid acquisition and lipid disposal, which includes four 
major pathways: uptake of circulating fatty acids, de novo lipogenesis (DNL), fatty acid 
oxidation (FAO), and export of lipids in very low density lipoproteins (VLDL) [9]. 
The uptake of circulating fatty acids by the liver is predominately reliant on fatty 




inside the hepatocyte plasma membrane [11, 12]. The two main FATP isoforms found in 
the liver are FATP2 and FATP5 [12]. The fatty acid translocase protein, CD36, transports 
long-chain fatty acids and is controlled by peroxisome proliferator-activated receptor-
gamma (PPARγ), pregnane X receptor, and liver X receptor [9]. The caveolins are 
membrane proteins that contribute to lipid trafficking and the creation of lipid droplets [12]. 
After uptake of fatty acids, hydrophobic fatty acids must be transferred between different 
organelles by specific fatty acid-binding proteins (FABP) such as FABP1 because they 
cannot diffuse freely in the cytosol [11]. FABP1 is the predominant isoform in the liver and 
helps with the storage, transportation, and utilization of fatty acids and their acyl-CoA  
derivatives [11, 12].  
The DNL pathway allows the liver to create new fatty acids from acetyl-CoA [9]. 
First, acetyl-CoA is turned into malonyl-CoA by acetyl-CoA carboxylase (ACC), and 
malonyl-CoA is changed into palmitate by fatty acid synthase (FASN) [9]. New fatty acids 
may undergo a series of desaturation, elongation, and esterification steps before being 
stored as triglycerides or distributed as VLDL particles [9]. Therefore, increased DNL can 
cause NAFLD since saturated fatty acids, such as palmitate, cause inflammation, and 
apoptosis [9]. 
The peroxisome proliferator-activated receptor alpha (PPARα) controls  the FAO 
pathway and occurs primarily in the mitochondria, which generates adenosine 
triphosphate (ATP), mainly when circulating glucose levels are low [9]. In mammalian 
cells, the peroxisomes, mitochondria, and cytochromes mediate FAO [13, 14]. In the outer 
mitochondrial membrane, carnitine palmitoyltransferase 1 alpha (CPT1α) facilitates the 




chain fatty acids and preferably metabolize via peroxisomal beta (β)-oxidation [15, 16]. 
The activation of PPARα induces the transcription of a range of genes related to FAO in 
the mitochondria (medium- and long-chain acyl-CoA dehydrogenases), peroxisomes 
(acyl-CoA oxidase (ACOX) 1 and enoyl-CoA hydratase), and cytochrome-mediated 
(CYP4A1 and CYP4A3) [13, 16-18]. Oxidative damage and lipid oxidation to 
mitochondrial DNA diminish mitochondrial function, creating a vicious cycle to aggravate 
mitochondrial dysfunction and oxidative stress [16]. 
Oxidative stress causes the imbalance between the factors that generate reactive 
oxygen species (ROS) and those that protect the antioxidant system, which leads to 
structural modifications of biomolecules, loss of cell signaling and gene expression 
control, and apoptosis [19-22]. The induction of oxidative stress resulting from 
mitochondrial oxidation of fatty acids leads to lipid peroxidation, advanced glycation end 
products (AGEs), and chronic inflammation, which are involved in the progression of 
NAFLD [23]. AGEs are molecules produced by in vivo glycation and oxidation or can 
occur in foods that reach elevated temperatures, such as frying and grilling [24]. Glycation 
occurs when reducing sugars or oxidized lipids react with the epsilon (ε)-side of amino 
acids in proteins, amino phospholipids, or nucleic acids without enzymatic regulation and 
are the primary cause of internal and external protein damage [23]. The formation of 
unstable Schiff bases in glycation undergoes rearrangements, which generates Amadori 
products that make the structure more stable and are the first products of the Maillard 
reaction [23]. Amadori products give rise to AGEs due to their reactive carbonyl groups 






Figure 1.1. Formation of AGEs from reducing sugars. Amadori product formed from a 
nucleophilic attack on the anomeric carbon of the sugar by lysine. After consecutive 
displacements, the intermediate α-dicarbonyl dideoxyinosine will form. The α-dicarbonyl 
intermediate undergoes a nucleophilic attack on the carbonyl group by the ε-amine, giving 
aldimine, a precursor for cross-linking agent Lysine-Arginine, to form glucosepane. C-1, 




Typically, glycation occurs slowly; however, under conditions of lipid peroxidation, 
the generation of AGEs increases drastically [23]. AGEs can cross-link with specific 
molecules by changing the chemical and biological properties or by interacting with matrix 
proteins and specialized receptors such as receptors for advanced glycation end products 
(RAGE) [23]. Oxidative stress stimulates AGEs/RAGE interaction by increasing the 
production of ROS and activating transcription factors, which lead to local tissue damage 
and higher inflammatory responses [23].  
The liver has immune cells that try to cope with stress by recruiting cells such as 
macrophages or monocytes in response to injury by emitting pro-inflammatory signals, 
including cytokines, chemokines, and ROS [23]. The expression of inflammatory 
cytokines and chemokines plays a significant role in the pathogenesis of NAFLD [25]. 
Pathogen-Associated Molecular Patterns (PAMPs) refer to many bacterial products such 
as lipopolysaccharide (LPS), derived from the cell wall of gram-negative bacteria, and 
other molecules such as peptidoglycans, bacterial lipoprotein flagellins, bacterial RNA 
and DNA, which can reach the liver upon disturbance of the intestinal mucosal barrier 
and trigger innate immune cells, causing intracellular signaling cascades that intensify 
injury [26]. LPS binds to specific receptor-activating toll-like receptors (TLRs) such as 
TLR4 and TLR9 and can activate Interleukin (IL)-1β, IL-18, IL-8, IL-6, IL-12, and TNF-α, 
which subsequently induce inflammation and fibrosis [26-29].  
The last pathway is the export of triglycerides which is the only way to diminish 
hepatic lipid content [30]. Fatty acids are hydrophobic and must be packed into water-
soluble VLDL particles along with apolipoproteins, cholesterol, and phospholipids before 




apolipoprotein B100 (apoB100) is lipidated via the enzyme microsomal triglyceride 
transfer protein (MTTP) [9]. The developing VLDL particle must be further lipidated until 
it forms a mature VLDL particle, and this process occurs during transportation to the Golgi 
apparatus [31]. The apoB100 is required for VLDL export, while the triglyceride content 
varies [32, 33]. Both components, apoB100 and MTTP, are crucial in sustaining hepatic 
lipid homeostasis and hepatic VLDL secretion [9]. When the export does not occur, this 
results in hepatic lipid overload and intracellular lipid accumulation, which leads to 
steatosis, lipotoxicity, liver damage, and fibrosis [9].   
1.3. Risk Factors for Non-Alcoholic Fatty Liver Disease 
The primary risk factors for NAFLD include obesity, atherogenic dyslipidemia, 
hypertension, insulin resistance (IR) and glucose intolerance, CVD, genetics, and 
ethnicity [34]. Many rare genetic conditions can cause dysfunction of the standard 
processing of nutrients and lipids inside the liver [35]. Also, ethnicity plays a part in which 
Hispanics have the highest prevalence of NAFLD, followed by non-Hispanic whites and 
then African Americans [1]. The secondary risk factors include family history, gender, age, 
polycystic ovary syndrome, environmental toxins, medications, obstructive sleep apnea 
[34]. In terms of heritability, a fatty liver is significantly more common in siblings (59%) 
and parents (78%) of children with NAFLD [36]. Men have an increased prevalence of 
NASH, and women typically develop the disease later than men do [37]. The major 
contributors that cause these risk factors to develop are the Western diet that causes 






1.3.1. Western Diet 
The rapid increase in the prevalence of obesity, metabolic syndrome, and NAFLD 
all relate to the Western diet, which often consists of excessive caloric intake due to the 
increased consumption of elevated levels of sugar and fat with a sedentary lifestyle [38]. 
The liver is a vital organ for protein, fats, and carbohydrate metabolism, catabolism, and 
excretion of toxins [39]. Any functional impairment can affect the whole organism, which 
can lead to morbidity and mortality [39]. Globally, fructose consumption has increased 
over the last decade [39]. Fructose is a monosaccharide that is naturally present in fruit 
and honey and has a high sweetness over other sugars [40]. Fructose is also a significant 
component in sucrose also known as table sugar, which is a disaccharide of fructose and 
glucose, and in high fructose corn syrup (HFCS) which is a mixture of fructose and 
glucose monosaccharides [40]. Sucrose and HFCS are considered risk factors for NAFLD 
and obesity [39, 40]. Studies in humans show that fructose induces DNL and inhibits fatty 
acid oxidation in the liver [41-45]. Glucose is a crucial energy source for the entire body 
and is metabolized mainly by glucokinase or hexokinase [40]. Fructose metabolism 
occurs mostly in the liver and is principally metabolized by fructokinase [40].  The major 
isoform of fructokinase in the liver is fructokinase C, which phosphorylates fructose 
quickly and causes a reduction of ATP and intracellular phosphate [40]. The decrease in 
intracellular phosphate stimulates the enzyme, adenosine monophosphate (AMP) 
deaminase, that changes AMP to inosine monophosphate (IMP), resulting in the 
formation of uric acid [40]. The fall in ATP levels causes multiple reactions to occur, 
including a brief block in protein synthesis, an induction in oxidative stress, and 




fructose in the liver and is highly expressed in the small intestine [40]. The metabolism of 
fructose in the intestine results in an altered gut microbiome which increases gut 
permeability through the loss of tight junctions [40]. Consequently, endotoxin gets into the 
portal vein and triggers the formation of a fatty liver, leading to the progression of NAFLD 
[40].  
In NAFLD, a fatty liver is the consequence of the excessive build up of various 
lipids [49]. Triglycerides are the most common type of lipids in the fatty liver [49]. Palmitic 
(C16:0) and oleic (C18:1) acids are the most common FFAs in liver triglycerides [50]. 
Fatty acids can come from the diet or synthesize in cells through metabolic pathways 
such as DNL [2]. Depending on the nutrient and energy environments, fatty acids can be 
quickly oxidized in peroxisomes and mitochondria to sustain the cellular bioenergetic 
homeostasis [51]. This ability to completely oxidize fatty acids to create energy occurs in 
most mammalian cells, but mature red blood cells depend only on glucose utilization to 
yield adequate amounts of ATP for survival [52]. There are different types of fatty acids 
with specific properties based on chain length and degree of saturation [53]. Palmitic acid, 
a saturated long-chain fatty acid, can be produced from the diet or endogenously from 
other fatty acids, carbohydrates, and proteins [54]. In autoimmune diseases, palmitic acid 
enhances the differentiation of naive T cells into T helper 1 (Th1) and T helper 17 (Th17) 
cells, promoting inflammation through activation of the p38 mitogen-activated protein 
kinases (MAPK) pathway [55]. Oleic acid, a monounsaturated long-chain fatty acid, is 






1.3.2. Gut Microbiota 
A delicate balance between gut microbiota, intestinal epithelial cells, and gut 
mucosal system is vital to sustaining intestinal permeability and tissue homeostasis [56]. 
When the gut microbiota becomes imbalanced inside the body, this refers to gut 
dysbiosis. The gut-liver axis is the concept of gut bacteria affecting liver homeostasis from 
the interaction between the gastrointestinal tract and the liver [57]. The liver is the first 
organ to drain the gut through the portal vein and plays a vital role in host-microbe 
interactions [57]. The portal blood contains molecules and nutrients that cross from the 
gut to the blood, which makes the liver one of the most exposed organs to intestinal 
bacteria and bacterial-derived products (Figure 1.2.) [58]. The disturbances of the gut–
liver axis include gut barrier disruption, bacterial translocation, inflammatory response in 
the liver, and changes in the composition of bacterial products [57]. Microbiome-derived 
compounds affect the hepatocytes by small molecules that lead to pro-inflammatory 
signaling, variations in gene expression, and modifications in metabolism and toxicity [57]. 
Bile acids in the small intestine promote the release of β-Klotho, a membrane protein, that 
affects hepatic synthesis [59]. β-Klotho binds to its receptor, farnesoid X receptor (FXR), 
inside the intestinal epithelial cells and travels to the liver through portal vein [57]. The β-
Klotho binds to fibroblast growth factor receptor 4 (FGFR4) on the surface of hepatocytes 
and causes an altered metabolism [57]. Bile acids also stimulate the Takeda G-coupled 
receptor 5 (TGR5) on the Kupffer cells, which produce the secretion of pro-inflammatory 
cytokines that cause pro-inflammatory signaling to hepatocytes [57]. Peptidoglycan and 
LPS, bacterial pattern molecules, signal Toll-like receptor 2 (TRL2), and Toll-like receptor 




receptor 43 (GPCR) GPR43 and alters metabolism, while butyrate acts as a histone 
deacetylase (HDAC) inhibitor and regulates gene expression [57]. Phenylacetate has an 
unknown mechanism that affects the expression of metabolic genes, FASN and 
lipoprotein lipase (LPL), which cause metabolic changes [57]. Lastly, the toxic derivative 
of ethanol, acetaldehyde, causes high oxidative stress on the hepatocytes [57].  
 
 
Figure 1.2. Gut microbiota-derived compounds affecting liver metabolism [57]. 
 
The healthy intestinal epithelium is an impenetrable physical barrier that keeps the 
host separate from the contents of the gut [57]. Tight junctions are essential regulators of 




bloodstream under physiological conditions [60]. However, regulation becomes 
pathological with the disruption of tight junctions and extreme paracellular leakage of non-
self antigens to the lamina propria, which leads to the progression of NAFLD and NASH 
[57].  
 
Figure 1.3. The intact (A) and disrupted (B) gut barrier.  
The gut barrier consists of tight junctional complexes, a mucous layer produced by goblet 
cells, antimicrobial resistance facilitated by Paneth cells, and the complex network of 
innate and adaptive immune cell populations (Figure 1.3.) [57]. Gut barrier disruption 




which initiates or enhances liver inflammation [57]. Multiple clinical and experimental data 
have confirmed that LPS significantly contributes to the development of obesity-related 
inflammatory liver diseases such as NAFLD and NASH [27, 61]. 
1.4. Treatment Options 
The two main treatment options for NAFLD are dietary changes and lifestyle 
modifications. In some cases, body weight loss is not achievable. Therefore, a few 
recommendations include medications and supplements; however, there are multiple 
side effects. Unfortunately, the lack of understanding of this disease makes prevention a 
challenging option.    
1.4.1. Therapeutic Approach  
  The most common antioxidant used in the treatment of NAFLD progression is 
Vitamin E [62]. However, the main concern for administrating vitamin E as a treatment is 
the possibility of producing toxic doses and could potentially cause prostatic cancer or a 
hemorrhagic stroke [62]. Vitamin E treatment is beneficial for patients with biopsy-proven 
NASH who are non-diabetics and should receive a lower dose (300–400 mg/day) [63].  
Pioglitazone treatment has been tested on NASH patients with prediabetes or type 2 
diabetes and is confirmed to be safe and effective during a 3-year study [64]. The negative 
concerns for pioglitazone include prostate or pancreas cancer, fluid retention, weight gain, 
and cardiovascular events [62]. Other therapies investigate pentoxifylline (improves 
hepatic steatosis), obeticholic acid (improves hepatic steatosis, inflammation, and 
fibrosis), orlistat (improves insulin resistance), ursodeoxycholic acid, statins, omega-3 
fatty acids, and glucagon-like peptide 1 receptor (GLP1R) agonists (improves hepatic 




1.4.2. Dietary Approach  
New opportunities arise for bioactive compounds found in specific foods to address 
inflammation in NAFLD. Bioactive fatty acids include a variety of structures, from simple 
to complex fatty acids, each playing multiple roles in the body such as cell proliferation, 
metabolic homeostasis, and regulation of inflammatory progressions [66, 67]. Bioactive 
fatty acids also play a part in biological effects in cell signaling pathways by adjusting lipid 
composition [55]. The dietary fatty acid composition is a significant factor in NAFLD 
development since 15% of liver triglycerides come from the diet [68]. The diet can expose 
the liver to several types of lipids, such as fatty acids, cholesterol, and triglycerides [69].  
1.4.2.1. Short-Chain Fatty Acids Significance  
Humans lack the necessary enzymes to degrade dietary fibers. These 
nondigestible carbohydrates pass into the upper gastrointestinal tract unchanged and are 
fermented by anaerobic microbiota in the cecum and the large intestine. The bacterial 
fermentation produces multiple groups of metabolites [70]. The major group produced is 
short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, which can 
differ from one to six carbons (Figure 1.4.) [71].  
 
Figure 1.4. Chemical structures of acetate, propionate, and butyrate  
SCFAs play a role in the prevention and treatment of various clinical studies due 
to their roles in energy homeostasis, cell proliferation, metabolic homeostasis, and 




cheese, and butter but can also be produced by bacteria from resistant starches and 
dietary fiber [69, 72]. Butyrate is the primary energy source for colonocytes, and the 
remaining fraction goes through the hepatic portal vein to the liver [69]. Butyrate maintains 
cellular homeostasis in the intestine, stimulates cell proliferation in normal colonocytes, 
and inhibits cell proliferation in cancer cell lines in vitro [73]. Propionate is considered a 
substrate for hepatic gluconeogenesis [74]. In the liver, 90% of propionate is absorbed, 
and the rest sent into the peripheral blood system [75]. Propionate has beneficial anti-
inflammatory properties, antihypertensive effects, cardioprotective effects, and influences 
T helper cell homeostasis [76].  
1.4.2.2. Biosynthesis and Metabolism of Short-Chain Fatty Acids 
The microbial transformation of dietary fiber to monosaccharides inside the gut 
involves multiple reactions facilitated by the enzymatic supply of specific gut microbiota 
(Figure 1.5.) [75]. The result of these fermentations leads to the production of SCFAs. 
Acetate comes from pyruvate via the acetyl-CoA route or the Wood-Ljungdahl pathway 
[75]. Next, acetate can form through two different branches, the Eastern branch via 
reduction of CO2 to formate or the Western branch via reduction of CO2 to CO, which is 
united with a methyl group to yield acetyl-CoA [75]. Propionate starts as 
phosphoenolpyruvate (PEP) via the succinate pathway, where succinate turns into 
methylmalonyl-CoA, and lastly, propionyl-CoA into propionate [75]. Other pathways 
include the acrylate pathway where the reduction of lactate produces propionate or the 
propanediol pathway, where deoxyhexose sugars such as fucose and rhamnose are 




yielding acetoacetyl-CoA, which converts to butyryl-CoA via β-hydroxybutyryl-CoA and 
crotonyl-CoA [75].  
Figure 1.5. Pathways for the biosynthesis of short-chain fatty acids from dietary fiber  
Once the generation of SCFAs occurs, they can enter the cells via 
monocarboxylate transporters (MCTs), passive diffusion, or exchange with bicarbonate 




Table 1.1. [77]. After transportation, the colonocytes absorb the SCFAs and enter the 
citric acid cycle inside the mitochondria to generate ATP and energy for the cells [78]. All 
three SCFAs via oxidation enter hepatocytes inside the liver as energy substrates or for 
the biosynthesis of glucose, cholesterol, and fatty acids [77].  
Table 1.1. Short-Cain Fatty Acid Transporters 
Transporter Localization in the Body Localization in the 
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1.4.2.3. Mechanism of Short-Chain Fatty Acids 
The role of SCFAs involves cellular signaling pathways and their interaction with 
gut-brain pathways, which include immune, endocrine, vagal, and other humoral 
pathways (Figure 1.6.) [77].  
Figure 1.6. The gut-brain pathways where SCFAs may modify or control brain function. 
BDNF, brain-derived neurotrophic factor; GDNF, glial cell line-derived neurotrophic factor; 
HPA, hypothalamus-pituitary-adrenal; NGF, nerve growth factor; TH1, T helper 1; TH17, 
T helper 17; Treg cell, regulatory T cell. 
 
Through the immune pathway, SCFAs can improve barrier integrity by 
upregulating the expression of tight junction proteins and increasing transepithelial 
electrical resistance (TEER) [77]. SCFAs can also activate free fatty acid receptors 




HDAC [77]. Histone acetylation begins as a fundamental switch that permits the 
interconversion between acetylation and deacetylation [77]. The removal of acetyl groups 
of histone tails occurs by HDAC inhibitors, while the additional acetyl groups of histone 
tails occur by histone acetyltransferases (HATs) [77]. Many studies report that HDAC 
inhibitors are involved in cancer therapy, brain development, and a range of 
neuropsychiatric diseases, including depression, schizophrenia, Alzheimer’s disease, 
and addiction [79]. Butyrate and propionate are both known to act as HDAC inhibitors 
which possess antiproliferative effects, anti-inflammatory properties, reduce insulin 
resistance, and stimulate hepatic fatty acid β-oxidation [80, 81]. SCFAs via HDAC 
inhibition can also regulate cytokine expression in T cells and the production of Treg [82]. 
Butyrate is the most investigated SCFA due to its high presence in the gut lumen, and 
primary energy source for colonocytes [83]. Normal colonocytes oxidize butyrate, 
whereas nuclear extracts from cancer cells accumulate butyrate 3-fold [84]. Therefore, 
butyrate can act as an efficient HDAC inhibitor in cancerous cells and a HAT activator in 
healthy cells. Through HDAC inhibition, butyrate makes the immune system 
hyporesponsive to beneficial commensals by suppressing pro-inflammatory effectors in 
lamina propria macrophages [77]. The beneficial health outcomes of using SCFAs 
includes their HDAC-inhibiting activity, high abundance (mM range), and energetics of 
cells using fatty acids for energy and generation of ATP versus glycolysis.   
The endocrine pathway is when SCFAs interact with their receptors on 
colonocytes, which induce indirect signaling to the brain by inducing the secretion of gut 
hormones such as glucagon-like peptide 1 (GLP1) and peptide YY (PYY) from 




These hormones impact learning, memory, and mood [77]. SCFAs can also signal to the 
brain by directly activating vagal afferents via FFAR [85]. Propionate can activate GPCRs, 
FFAR-2 and FFAR-3, also known as GPR43 and GPR41, respectively [81]. Propionate 
has the highest rank order of potency compared to acetate and butyrate in both GPR41 
and GPR43 [86]. The mechanism of propionate involves changing invasive phenotypes 
to non-invasive phenotypes [87]. GPR41 is in the gut, adipose tissue, and the peripheral 
nervous system (PNS), while GPR43 is in adipose tissue, immune cells, and the intestine 
[88]. GPR43 releases PYY and GLP-1, affecting satiety and intestinal transit [89]. GPR41 
signaling involves propionate-induced intestinal glucogenesis by gut-brain neurocircuitry 
[90]. Both propionate and butyrate increase intestinal glucose production; however, 
butyrate directly upregulates intestinal glucogenesis genes (G6PC and PCK1), while 
propionate does indirectly [91]. Propionate receptor GPR41 is present in the nerve fibers 
of the portal vein wall and can send signals to the peripheral and central nervous system 
(CNS) areas to induce intestinal gluconeogenesis [77]. Butyrate can signal GPR109A, 
which exerts immune-suppressive mechanisms by increasing IL-18 secretion, generating 
Treg, and IL-10 producing T cells via signaling [92]. GPR109A is a receptor for nicotinate 
(niacin) and facilitates lipid-lowering mechanisms [92]. The signaling of GPR109A is 
present on adipocytes, immune cells, and colonocytes [92]. Through the binding of 
GPCRs, SCFAs may affect the CNS and PNS, which is a qualification for their assumed 
effects on psychological developments. 
Lastly, SCFAs can cross the blood-brain barrier (BBB) via monocarboxylate 
transporters located on endothelial cells and influence BBB integrity by inhibiting 




neurotrophic factors centrally, via histone acetylation and can contribute to the 
biosynthesis of serotonin [83, 93]. Together, the interaction of SCFAs with these gut-brain 
pathways can directly or indirectly modulate processes associated with neural 
functioning, learning, memory, and mood.  
1.5. Research Objective and Hypothesis  
 NAFLD is the most common cause of chronic liver disease [5]. Unfortunately, 
patients are asymptomatic in the early stages, which makes diagnosis difficult [5]. 
Currently, the only treatment is regular exercise and a healthy diet. The main objective of 
this doctoral dissertation research is to evaluate the mechanisms behind sodium butyrate 
(NaB) and sodium propionate (NaP), which could potentially serve as bioactive 
compounds that relieve oxidative stress and inflammation in NAFLD progression. We 
hypothesize that NaP alone, NaB alone, or in combination, will promote FAO and reduce 
pro-inflammatory cytokines in HepG2 cells.  
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CHAPTER 2. SODIUM PROPIONATE AND SODIUM BUTYRATE PROMOTE FATTY 
ACID OXIDATION IN HEPG2 CELLS UNDER OXIDATIVE STRESS 
 
2.1. Introduction  
Non-alcoholic fatty liver disease (NAFLD) is a series of disturbances that involve 
various steps of liver damage including simple steatosis, which is fat accumulation in liver 
cells, to non-alcoholic steatohepatitis (NASH), fat build up plus inflammation in liver cells, 
that can eventually lead to hepatic fibrosis, cirrhosis, or liver cancer [1]. NAFLD affects 
individuals that consume the typical Western diet consisting of high levels of refined 
sugars, fats, and other refined carbohydrates such as starch. Consequently, the increase 
of circulating free fatty acids (FFAs) as a result of unhealthy white adipose tissue causes 
oxidative stress and liver inflammation. Palmitic acid, a saturated fatty acid, and oleic 
acid, a monounsaturated fatty acid, are the most abundant FFAs in the diet and fatty liver 
[2]. Palmitic acid is in palm oil, meat, dairy products, cocoa butter, olive oil, and breast 
milk [3, 4]. Oleic acid is mostly in olive and canola oil but also found in animal fats such 
as lard [5]. 
One important mechanism contributing to the development of NAFLD is gut 
dysbiosis, where the imbalance of gut bacteria affects liver homeostasis [6]. The liver is 
the first organ to drain the gut through the portal vein and plays a vital role in host-microbe 
interactions [6]. The portal blood contains water-soluble molecules and nutrients that 
cross from the gut to the blood, which makes the liver one of the most vulnerable organs 
to intestinal bacteria and bacterial-derived products [6]. A leaky and inflamed gut can lead 
to the translocation of lipopolysaccharide (LPS), which comes from the cell wall of gram-




disorders, inflammation, a Western diet with overconsumption of energy, oxidative stress, 
and the changes in gut microbiota might result from LPS exposure [7]. The liver, in 
response to the elevated levels of palmitic and oleic acid or LPS, activates the release of 
numerous pro-inflammatory cytokines, such as Interleukin (IL)-8, IL-6, and Tumor 
Necrosis Factor alpha (TNF-α), within the liver microenvironment [8, 9].  
One of the major pathways disrupted in NALFD is fatty acid oxidation (FAO), which 
occurs primarily inside the mitochondria and generates adenosine triphosphate (ATP) 
[10]. Peroxisome proliferator-activated receptor alpha (PPARα), a transcriptional activator 
of hepatic lipid metabolism genes such as carnitine palmitoyltransferase 1 alpha (CPT1α), 
controls the FAO pathway [11]. CPT1α is the rate-limiting enzyme of fatty acid beta (β)-
oxidation because it is involved in getting palmitic acid across the outer mitochondrial 
membrane into the mitochondrial matrix  [12, 13]. In NAFLD patients, both PPARα and 
CPT1α levels significantly decrease in comparison to a healthy liver [14]. Short-chain fatty 
acids (SCFAs) such as butyrate and propionate can activate free fatty acid receptors 
(FFARs) by inhibiting histone deacetylases (HDAC), leading to greater gene expression 
for FAO genes, which stimulates hepatic fatty acid β-oxidation [15]. Many studies report 
that HDAC inhibitors possess anti-proliferative effects, anti-inflammatory properties, and 
regulate cytokine expression [16-18]. Butyrate is found in butter, parmesan cheese, and 
the lipid component of dairy milk, but can also form from resistant starches and dietary 
fiber in the large intestine [19, 20]. After absorption of butyrate, colonocytes use it as their 
primary source of energy, and the remaining fraction goes through the hepatic portal vein 
to the liver [19]. Butyrate has beneficial effects that include anti-inflammatory properties, 




intestinal barrier function, and helps reduce body weight [20, 21]. Butyrate also has low 
systemic toxicity, which makes it an excellent agent for clinical trials. Propionate can 
provide energy for epithelial cells and is considered a substrate for hepatic 
gluconeogenesis [22]. The liver absorbs about 90 % of propionate, and the rest is sent 
into the peripheral systemic blood [14]. Propionate has beneficial anti-inflammatory 
properties, anti-hypertensive effects, and cardioprotective effects [23]. Both butyrate and 
propionate reduce food intake, weight gain, and high blood sugar [24]. 
In this study, we are evaluating the mRNA expression of genes associated with 
fatty acid metabolism and the protein expression of pro-inflammatory cytokines related to 
NAFLD using the HepG2 human liver hepatocellular carcinoma cells exposed to palmitate 
and oleate or LPS. The mechanisms behind sodium butyrate (NaB) or sodium propionate 
(NaP) could potentially serve as bioactive compounds that relieve oxidative stress and 
inflammation in liver cells. We hypothesize that NaB or NaP or in combination will promote 
FAO and reduce pro-inflammatory cytokines in HepG2 cells.  
2.2. Materials and Methods 
2.2.1. Reagents  
Radioimmunoprecipitation assay (RIPA) buffer (#89900), protease inhibitors 
(#5871S), phosphatase inhibitors (#5870S), Gibco™ fetal bovine serum (FBS) 
(#26140079), phosphate buffer solution (PBS) (#10010023), Gibco™ 
gentamicin/amphotericin solution (#R01510) and Gibco™ 1X minimum essential medium 
(MEM) (#11095072), and Ambion® RNAsecure™ (#AM7005)  were obtained from 
ThermoFisher Scientific (Waltham, MA). TRl reagent (#T9424), fatty acid free-bovine 




O111:B4 (#L4391), penicillin-streptomycin (#P0781), and 1-Bromo-3-chloropropane 
(BCP) (#B9673) were obtained from Sigma Aldrich (St. Louis, MO). Sodium palmitate 
(#P0007), sodium oleate (#O0057), sodium butyrate (#S0519), and sodium propionate 
(#P0512) were purchased from TCI America (Portland, OR).  
2.2.2. Palmitate and Oleate Preparation 
Stock solutions of 5mM sodium palmitate and 10mM sodium oleate were prepared 
in MEM with 10% defatted BSA. Briefly, sodium palmitate was dissolved in PBS and then 
heated at 70˚C until completely clear, and quickly added to preheated MEM 37˚C. Sodium 
oleate was directly added to preheated MEM. All preparations were filtered and stored at 
4˚C. 
2.2.3. Sodium Butyrate and Sodium Propionate Preparation 
The 100mM stock solutions were prepared for NaB and NaP in PBS.  All 
preparations were filtered and stored at 4˚C.  
2.2.4. Cell Line and Culture Conditions 
The HepG2 human hepatocellular carcinoma cells (ATCC HB-8065, Manassas, 
VA) were maintained in MEM with 10% FBS and 1% antibiotic 
(penicillin/streptomycin/amphotericin) at 37°C in a humidified atmosphere containing 95% 
air and 5% CO2. Just before reaching 80% confluence, cells were split (1:6) by 
trypsinization into 6, 24, or 96-well plates in MEM with 10% FBS and 1% antibiotic 
(penicillin/streptomycin/amphotericin) for 24h. All experimental treatments were 
conducted in MEM with 10% heat-inactivated FBS (inactivated by heating for 30 minutes 
at 56°C) and 1% antibiotic (penicillin/streptomycin/amphotericin) which was the vehicle 




coli O111:B4 (1ug/ml) in some experiments. In other experiments, cells were preloaded 
with a combination of palmitate (0.5mM) and oleate (0.5mM) for 24h. After 24h, cells were 
treated with various concentrations of NaB (2, 4mM), NaP (2, 4, and 8mM), or a 
combination of NaB (2mM) and NaP (4mM) for another 24h in the presence of LPS or the 
combination of palmitate and oleate.  
2.2.5. Cell Viability using MTS Assay 
The MTS assay (#G3582) was used to test cell viability from Promega (Madison, 
WI). The HepG2 cells were plated in a 96-well at 5 × 103 cells per well and treated with 
different concentrations of palmitate and oleate combined (0.5, 1, 2mM), LPS (400, 800, 
1000 ng/ml), NaP (2, 4, 8mM), and NaB (2, 4, 8mM) for 24h. CellTiter 96® AQueous One 
Solution Reagent (100ul) was directly added to each cell culture well, incubated for 1h at 
37°C in a humidified atmosphere containing 5% CO2, and then absorbance was recorded 
at 490nm using the BioRad Model 680 microplate reader (Hercules, CA). The quantity of 
formazan product measured at 490nm absorbance is directly proportional to the number 
of living cells in culture. The relative cell viability equation was used to determine the 
percentage of living cells.  
2.2.6. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
In a 24-well plate, cells were exposed to LPS from Escherichia coli O111:B4 
(1µg/ml) or with a combination of palmitate (0.5mM) and oleate (0.5mM) for 24h. After 
24h, cells were treated with various concentrations of NaB (2, 4mM), NaP (2, 4, and 
8mM), or a combination of NaB (2mM) and NaP (4mM) for another 24h in the presence 
of LPS or the combination of palmitate and oleate. After 24h treatment, cell media was 




from cells using TRI Reagent and purified with the RNeasy Mini Kit (#74104) from Qiagen 
(Hilden, Germany). Briefly, cell homogenates were stored at room temperature for 5 
minutes. Next, BCP (50µl) was added to each sample to facilitate the separation of 
organic (proteins) and aqueous phases (RNA). The samples were shaken by hand 
vigorously for 20 seconds, stored at room temperature for 5 minutes, and centrifuged at 
12,000 rpm for 15 minutes at 4˚C to clarify phases. The upper aqueous phase containing 
total RNA (200µl) was removed, added to ice-cold 100% RNA-free ethanol (220µl), and 
loaded onto RNeasy mini spin columns. The columns were washed with RW1 and RPE 
buffers to remove DNA and protein. Lastly, columns were transferred to new collection 
tubes with RNAsecure (1µl). Total RNA was eluted in RNase-free water (50ul) and stored 
at -80˚C until use.  
The Qubit RNA BR Assay (#Q10210) and Qubit Fluorometer from ThermoFisher 
Scientific (Waltham, MA) were used to quantify RNA concentrations. Reverse 
transcriptase and qPCR were conducted sequentially in each reaction with the reverse 
PCR primer serving to prime cDNA synthesis using Superscript III Platinum One-Step 
Quantitative RT-PCR System (#11732020) from ThermoFisher Scientific (Waltham, MA). 
Primer and probe sets were purchased from Applied Biosystems (Pleasanton, CA) (Table 
2.1.). Ribosomal Protein L13a (RPL13A) (Taqman® ID Hs04194366_g1, Thermofisher 
Scientific, Waltham, MA.) was used as a housekeeping gene. The RT-PCR assay for 
each sample was performed each time in duplicate using the protocol for Applied 



















NCBI Reference  
ATGL Forward (5'-3') CGTGTACTGTGGGCTCATC NM_020376.3 
 Reverse (3'-5') GGACACTGTGATGGTGTTCTTA  
 Probe ATGGTGGCATTTCAGACAACCTGC  
CPT1α Forward (5'-3') GCGTTCTTTGTGACGTTAGATG NM_001876.3 
 Reverse (3'-5') CGGCCGTGTTAGTAGAGATTTG  
 Probe AGAAGGATACAGAAGTGAAGACCCGGA  
FGF21 Forward (5'-3') GAGTCAAGACATCCAGGTTCC NM_019113.4 
 Reverse (3'-5') GTATCCGTCCTCAAGAAGCAG  
 Probe CCTCAGGGTCAAAGTGGAGCGATC  
PGC-1α Forward (5'-3') CACCAAACCCACAGAGAACA NM_00145134.1 
 Reverse (3'-5') GGGTCAGAGGAAGAGATAAAGTTG  
 Probe AAAGAAGTCCCACACACAGTCGCA  
PPARα Forward (5'-3') GTCGATTTCACAAGTGCCTTTC XM_011530239.2 
 Reverse (3'-5') CAGGTAAGAATTTCTGCTTTCAGTT  
 Probe AACGAATCGCGTTGTGGTGACATCC  
UCP2 Forward (5'-3') CTACAAGACCATTGCACGAGAGG NM_003355.2 
 Reverse (3'-5') AGCTGCTCATAGGTGACAAACAT  
 Probe CCTCAGGGTCAAAGTGGAGCGATC  
ATGL, adipose triglyceride lipase; CPT1α, carnitine palmitoyltransferase I alpha; FGF21, fibroblast 
growth factor 21; NCBI, National Center for Biotechnology Information; PGC-1α, peroxisome 
proliferator-activated receptor gamma coactivator l alpha; PPARα, peroxisome proliferator activated 





2.2.7. ELISA Analysis of TNF-α and IL-8 
The cells were plated in 24-well plates and stimulated with LPS from Escherichia 
coli O111:B4 (1ug/ml) or with a combination of palmitate (0.5mM) and oleate (0.5mM). 
After 24h, cells were treated with various concentrations of NaB (2, 4mM), NaP (2, 4, and 
8mM), or a combination of NaB (2mM) and NaP (4mM) for 24h in the presence of LPS or 
the combination of palmitate and oleate. After 24h treatment, culture plates were put on 
ice, each well was washed with ice-cold PBS, and cells were scraped into ice-cold RIPA 
buffer (300µl) containing protease and phosphatase inhibitors. Samples were pushed 
through an ice-cold 20G syringe needle four times to disrupt organelles and centrifuged 
at 12,000 rpm for 5 minutes. Cell supernatants were collected and immediately stored at 
-80˚C until further use.  
The levels of TNF-α (15.6pg/ml-1000pg/ml) (#EK0525) and IL-8 (15.6pg/ml-
1000pg/ml) (#EK0413) were analyzed using ELISA kits from Boster Bio (Pleasanton, CA) 
following manufacturer’s instructions. All samples were diluted using sample diluent 
provided in each ELISA kit at 1:25 for the LPS model and 1:50 for the palmitate and oleate 
model. The absorbance of each cytokine (pg/ml) was read at 450nm using a BioRad 
Model 680 microplate reader (Hercules, CA). Each sample was done in triplicate, and the 
protein concentration (pg/ml) of each sample is determined based on the standard curve.  
2.2.8. Western Blot Analysis of CPT1α 
Cells were plated in 6-well plates and loaded with fat by exposure to a combination 
of palmitate (0.5mM) and oleate (0.5mM). After 24h, cells were treated with NaP (8mM) 
and the combination of NaB (2mM) and NaP (4mM) for 24h. Total cellular protein was 




cells were scraped into ice-cold RIPA buffer (300µl) containing protease and phosphatase 
inhibitors. Samples were pushed through an ice-cold 20G syringe needle four times to 
disrupt organelles and spun at 12,000 rpm for 5 minutes in a prechilled centrifuge to 
remove the insoluble fraction. Cell supernatants were collected and immediately stored 
at -80˚C until further use. The protein concentration in samples was quantified using the 
bicinchoninic acid assay (BCA) (#23227) from ThermoFisher Scientific (Waltham, MA).  
After BCA, to obtain equal sample volumes for loading on gels, RIPA buffer was 
added to each 50µg sample.  Next, 4X Laemmli sample buffer (#161-0747, Bio-Rad) 
mixed with 5% 2-mercaptoethanol (#M6250, Sigma-Aldrich) was added to each sample 
and boiled at 100˚C for 5 minutes to denature proteins. Samples were centrifuged and 
loaded onto TGX sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gels (7.5% TGX, Bio-Rad). Gels were run at 100V until the dye line was near the 
bottom. Proteins of interest were transferred to nitrocellulose membranes (#1620145, Bio-
Rad), then blocked in 5% bovine serum albumin (BSA) in tris buffered saline with 0.1% 
tween-20 (TBST)  for 1h. The primary antibody for β-actin (#A5316, Sigma) and CPT1α 
(#sc-393070, Santa Cruz Biotechnology, Inc.) were prepared in TBS with 4% BSA and 
0.5% tween-20 and incubated at room temperature for 3h. The membranes were washed 
three times for 5 minutes using TBST, then incubated for 1h with anti-mouse (#AP130P, 
Sigma-Aldrich) secondary antibody and washed three times for 5 minutes using TBST.  
Visualization of proteins was performed in a dark room using chemiluminescence 
(Western Lightning Plus-ECL, PerkinElmer, Waltham, Massachusetts). Densitometric 
analyses were done using ImageJ software (National Institutes of Health), and the relative 




2.2.9. Statistical Analysis 
All experiments were performed at least three times. The differences between 
samples were analyzed using a one-way analysis of variance (ANOVA) with Tukey’s 
honest significant difference (HSD) test. Significance was set at P < 0.05 level. The results 
are expressed as mean ± SE. Means with the asterisk (*) symbol indicate significantly 
different from the unstimulated control. Means with the pound (#) symbol indicate 
significantly different from LPS or palmitate/oleate. All analyses were performed using 
SAS 9.4 (SAS Institute, Cary, NC).  
2.3. Results 
2.3.1. Effect of Palmitate/Oleate, Lipopolysaccharide (LPS), and SCFAs on Cell Viability 
To investigate the impact of palmitate/oleate, LPS, NaP, and NaB on cell survival 
in HepG2 cells, various concentrations were used for 24h. The results were consistent 
with other studies, showing palmitate/oleate at 1mM (80% live cells) and 2mM (70% live 
cells) were significantly different from the control (100% live cells). In the LPS model, all 
concentrations were not significantly different from the control, which suggests that up to 
1ug/ml does not cause significant cell death in HepG2 cells. The concentrations of NaP 
and NaB were not significantly different from the control, which suggests that up to 8mM 
does not cause significant cell death in HepG2 cells.  
2.3.2. FAO and Mitochondrial Related Genes in the LPS Model 
The HepG2 cell line was used to investigate the response of NaP and NaB 
treatment in the LPS model. The dose of 1ug/ml for LPS has been used by others to 




The treatment of NaB, NaP, or in combination increased the mRNA expression of 
peroxisome proliferator-activated receptor-γ coactivator (PGC-1α), PPARα, CPT1α, and 
uncoupling protein 2 (UCP2).  
          
 
Figure 2.1. PGC-1α mRNA expression in HepG2 cells alone (control), in the presence of 
LPS, or in the presence of LPS and various concentrations of NaB, NaP, or NaB and NaP 
mixture. All data were normalized using RPL13α from three independent experiments. 
The results are presented as mean ± SE (n=6). *p < 0.05 represents significantly different 
from the control; #p < 0.05 represents significantly different from LPS. 
 
PGC-1α is a potent activator of FAO and controls hepatic gluconeogenesis [29]. PGC-1α 
expression was significantly increased in NaP 4mM by 1.49-fold in comparison to LPS 
and was significantly increased in NaP 8mM by 1.75-fold in comparison to the control and 






PGC-1α is also known to control the transcriptional activity of PPARα, an enzyme involved 
in lipid oxidation.  PPARα was significantly increased in NaB 2mM, NaB 4mM, NaP 4mM, 
NaP 8mM, and the combination of NaB 2mM and NaP 4mM by 1.28-fold, 1.33-fold,1.46-
fold, 1.68-fold, and 1.54-fold, respectively in comparison to LPS, while NaP 8mM and the 
combination of NaB 2mM and NaP 4mM was significantly different from the control 
(Figure 2.2.).  
  
 
Figure 2.2. PPARα mRNA expression in HepG2 cells alone (control), in the presence of 
LPS, or in the presence of LPS and various concentrations of NaB, NaP, or NaB and NaP 
mixture. All data were normalized using RPL13α from three independent experiments. 
The results are presented as mean ± SE (n=6). *p < 0.05 represents significantly different 






PPARα is also a transcriptional activator of CPT1α, which was significantly increased in 
NaB 2mM by 1.24-fold, NaB 4mM by 1.21-fold, and the combination of NaB 2mM and 
NaP 4mM by 1.37-fold in comparison to LPS (Figure 2.3.). However, there were no 
significant differences seen in CPT1α among all treatments against the control. 
 
 
Figure 2.3. CPT1α mRNA expression in HepG2 cells alone (control), in the presence of 
LPS, or in the presence of LPS and various concentrations of NaB, NaP, or NaB and NaP 
mixture. All data were normalized using RPL13α from three independent experiments. 
The results are presented as mean ± SE (n=6). *p < 0.05 represents significantly different 
from the control; #p < 0.05 represents significantly different from LPS. 
 
UCP2, a mitochondrial protein, is a regulator of mitochondrial reactive oxygen species 





The upregulation of UCP2 was significantly increased in NaB 2mM, NaB 4mM, NaP 4mM, 
NaP 8mM, and a combination of NaB 2mM and NaP4mM by 2.15-fold, 2.51-fold, 1.88-
fold, 2.18-fold, and 2.55-fold, respectively against the control and LPS; however, NaP 
4mM was not significantly different from the control (Figure 2.4.).   
 
 
Figure 2.4. UCP2 mRNA expression in HepG2 cells alone (control), in the presence of 
LPS, or in the presence of LPS and various concentrations of NaB, NaP, or NaB and NaP 
mixture. All data were normalized using RPL13α from three independent experiments. 
The results are presented as mean ± SE (n=6). *p < 0.05 represents significantly different 
from the control; #p < 0.05 represents significantly different from LPS. 
 
2.3.3. FAO and Mitochondrial Related Genes in the Palmitate/Oleate Model 
The oxidative stress and inflammation induced by palmitate/oleate was rescued by 
NaP and NaB treatment by upregulating mRNA expression of adipose triglyceride lipase 




ATGL is a key lipase in the liver. The treatments of NaB 2mM, NaB 4mM, NaP 4mM, NaP 
8mM, and the combination of NaB 2mM and NaP 4mM by 1.80-fold, 2.99-fold,1.43-fold, 
2.21-fold, and 2.55-fold, respectively, were significantly different in comparison to the 
control and palmitate/oleate (Figure 2.5.). 
 
 
Figure 2.5. ATGL mRNA expression in HepG2 cells alone (control), in the presence of 
palmitate/oleate, or in the presence of palmitate/oleate and various concentrations of 
NaB, NaP, or NaB and NaP mixture. All data were normalized using RPL13α from three 
independent experiments. The results are presented as mean ± SE (n=6). *p < 0.05 
represents significantly different from the control; #p < 0.05 represents significantly 
different from palmitate/oleate. 
 
ATGL also plays a role in PPARα signaling [30, 31]. The expression of PPARα was 
significantly increased in NaB 2mM, NaP 4mM, and NaP 8mM by 1.24-fold, 1.53-fold, 




The treatment of NaP 4mM and NaP 8mM was significantly different from the control. The 





Figure 2.6. PPARα mRNA expression in HepG2 cells alone (control), in the presence of 
palmitate/oleate, or in the presence of palmitate/oleate and various concentrations of 
NaB, NaP, or NaB and NaP mixture. All data were normalized using RPL13α from three 
independent experiments. The results are presented as mean ± SE (n=6). *p < 0.05 
represents significantly different from the control; #p < 0.05 represents significantly 
different from palmitate/oleate. 
 
The expression of CPT1α was significantly increased by 2.25-fold in NaP 8mM and in the 
combination of NaB 2mM and NaP 4mM by 2.30-fold in comparison to the control and 







Figure 2.7. CPT1α mRNA expression in HepG2 cells alone (control), in the presence of 
palmitate/oleate, or in the presence of palmitate/oleate and various concentrations of 
NaB, NaP, or NaB and NaP mixture. All data were normalized using RPL13α from three 
independent experiments. The results are presented as mean ± SE (n=6). *p < 0.05 
represents significantly different from the control; #p < 0.05 represents significantly 
different from palmitate/oleate. 
 
FGF21 expression, in comparison to the control and palmitate/oleate, were significantly 
upregulated in NaP 2mM and NaP 4mM by 1.97-fold and 2.21-fold, respectively (Figure 
2.8.). However, NaP 8mM and the combination of NaB 2mM and NaP 4mM were 








Figure 2.8. FGF21 mRNA expression in HepG2 cells alone (control), in the presence of 
palmitate/oleate, or in the presence of palmitate/oleate and various concentrations of 
NaB, NaP, or NaB and NaP mixture. All data were normalized using RPL13α from three 
independent experiments. The results are presented as mean ± SE (n=6). *p < 0.05 
represents significantly different from the control; #p < 0.05 represents significantly 
different from palmitate/oleate. 
 
2.3.4. Expression of TNF-α and IL-8 Levels 
The protein levels of TNF-α and IL-8, released from LPS-stimulated or 
palmitate/oleate-stimulated HepG2 cells were determined using ELISA. LPS is a potent 
inducer of TNF-α and was significantly increased (2112 pg/ml) in comparison to the 





All the treatments of NaB and NaP were not significantly different from the control in the 
LPS model. However, in comparison to LPS (2112 pg/ml), the treatment of NaP 8mM 
(1400 pg/ml) and the combination of NaB 2mM and NaP 4mM (1285 pg/ml) had 
significantly decreased TNF-α expression. 
 
 
Figure 2.9. TNF-α levels in HepG2 cells alone (control), with LPS, or in combination with 
various concentrations of NaB, NaP, or NaB and NaP. TNF-α levels were measured by 
ELISA. The results are presented as mean ± SE (n=3). *p < 0.05 represents significantly 
different from control; #p < 0.05 represents significantly different from LPS.  
 
In the palmitate/oleate model, the levels of TNF-α in all treatments were not significantly 





IL-8, also called neutrophil-activating peptide-1 or SCYB8, is a tissue-derived peptide 
secreted in response to stimulation by TNF-α.  
 
 
Figure 2.10. TNF-α levels in HepG2 cells alone (control), with palmitate/oleate, or in 
combination with various concentrations of NaB, NaP, or NaB and NaP. TNF-α levels 
were measured by ELISA. The results are presented as mean ± SE (n=3). *p < 0.05 
represents significantly different from control; #p < 0.05 represents significantly different 
from palmitate/oleate.  
 
IL-8 levels in the LPS model showed no significant differences among all treatments. The 
two treatments, NaB 2mM (244 pg/ml) and NaB 4mM (262 pg/ml), were able to reduce 
IL-8 levels more effectively, however were not statically significant in comparison to the 








Figure 2.11. IL-8 levels in HepG2 cells alone (control), with LPS, or in combination with 
various concentrations of NaB, NaP, or NaB and NaP. IL-8 levels were measured by 
ELISA. The results are presented as mean ± SE (n=3). *p < 0.05 represents significantly 
different from control; #p < 0.05 represents significantly different from LPS.  
 
In the palmitate/oleate model, like the LPS model, IL-8 levels showed no significant 
differences among all treatments (Figure 2.12.). The two treatments, NaB 4mM (1074 
pg/ml) and the combination of NaB 2mM and NaP 4mM (945 pg/ml), were able to lower 
IL-8 levels more successfully than all other treatments, however were not considered 









Figure 2.12. IL-8 levels in HepG2 cells alone (control), with palmitate/oleate, or in 
combination with various concentrations of NaB, NaP, or NaB and NaP. IL-8 levels were 
measured by ELISA. The results are presented as mean ± SE (n=3). *p < 0.05 represents 
significantly different from control; #p < 0.05 represents significantly different from 
palmitate/oleate. 
  
2.3.5. Effects of NaP and NaB on Carnitine Palmitoyltransferase 1 alpha (CPT1α) Levels 
 One of the key proteins in FFA metabolism is CPT1α. Therefore, protein levels of 
CPT1α were studied in palmitate and oleate-stimulated HepG2 cells by Western blotting. 
The results indicated that CPT1α, which is the rate-limiting enzyme of fatty acid β-








Figure 2.13. Western blot results of CPT1α levels in HepG2 cells alone (control), with 
palmitate/oleate (P/O), NaP 8mM (NaP8) with P/O, or NaB 2mM and NaP 4mM 
(NaB2/NaP4) with P/O. A) Protein levels of CPT1α and β-actin visualized by 
chemiluminescence. B) Densitometric analysis of the bands was performed using ImageJ 





The protein levels of CPT1α in the palmitate/oleate model were increased by NaP 8mM 
and the combination of NaB 2mM and Nap 4mM (Figure 2.13.).  
2.4. Discussion 
In this study, we investigated two major risk factors that lead to the progression of 
NAFLD. The combination of palmitate and oleate or LPS, which are generated by the 
over consumption of the Western diet. Both risk factors are known to cause gut dysbiosis, 
oxidative stress, and inflammation in the liver. We found that mRNA expression levels of 
multiple genes involved in FAO were upregulated by NaP and NaB. Studies prove that 
propionate and butyrate, but not acetate, act as HDAC inhibitors, which possess 
antiproliferative effects, anti-inflammatory properties, and stimulate hepatic FAO [24, 32, 
33]. Our results suggest that NaP and NaB can attenuate steatosis and liver injury by 
stimulating FAO and mitochondrial related genes, increasing protein expression of 
CPT1α, and regulating inflammation by decreasing pro-inflammatory cytokines.  
The LPS model, used to represent the consequence of gut dysbiosis, is 
significantly elevated in NAFLD human and animal studies [6]. The impact of LPS in 
HepG2 cells decreased PGC-1α, UCP2, PPARα, and CPT1α mRNA expression but was 
not significantly different from the control. There is evidence that indicates hepatocytes 
uptake and detoxifies LPS and could explain why LPS was not able to significantly reduce 
FAO related genes [34, 35]. However, we can confirm that LPS caused inflammation in 
HepG2 cells through TNF-α expression, which was significantly increased. In the liver, 
PGC-1α regulates energy homeostasis, controls gluconeogenesis, and interacts with 
genes such as PPARα, which is involved in FAO [29, 36]. Studies show that the dietary 




that in vitro, NaP is a novel activator of PGC-1α in the presence of LPS compared to cells 
treated with LPS only. The molecular mechanism of NaP could be the ability to stimulate 
hepatocyte mitochondrial content and function through PGC-1α activation [29]. 
Furthermore, NaP, NaB, and in combination, may play protective roles against 
mitochondrial oxidative damage since they significantly upregulated UCP2, a transport 
protein in the inner mitochondrial membrane, that reduces ROS production [37]. In 
NAFLD, FFA overload in the mitochondria increases ROS production and oxidative stress 
[38]. The molecular mechanism of NaP and NaB may be the ability to prevent 
mitochondrial oxidative stress and hepatic fat accumulation in NAFLD through UCP2 
promotion.  
We used the combination of palmitate and oleate to represent the fatty acid 
composition of Western diets seen in NAFLD patients. The effect of combined palmitate 
and oleate only numerically decreased the mRNA expression of FGF21, ATGL, PPARα, 
and CPT1α in HepG2 cells but was not significantly different from the control. Palmitate 
at high concentrations (> 0.5 mM) causes cytotoxicity via endoplasmic reticulum stress in 
hepatocytes, while oleate does not [39, 40]. Studies have shown that when combined, 
oleate may protect cells from palmitate-induced cellular stress and apoptosis through 
efficient incorporation of fatty acids into triglyceride-rich lipoproteins for export, thus 
channeling excess lipids away from toxic pathways [39, 41-44]. Cell viability results 
confirmed that the combination of palmitate and oleate was significantly different from the 
control, which suggests that palmitate and oleate together can cause cell death but not 
significant reductions in FAO. In the liver, FGF21 is highly expressed and increases FAO 




FGF21 at a transcriptional level [45]. In vivo and in vitro studies show that PPARα 
agonists can increase FGF21 expression [46-48]. Exogenous FGF21 administration has 
been shown to reduce plasma and hepatic triglycerides, reduce body weight, reverse 
hepatic steatosis, and increase whole-body energy expenditure in mice fed a high-fat diet 
[49]. We show for the first time that only NaP alone was able to significantly increase 
FGF21 expression in palmitate and oleate-induced HepG2 cells, which indicates its 
potential in stimulating FAO, improving lipid metabolism, and possibly reversing hepatic 
steatosis [50, 51]. We speculate that NaP uptake by the liver explains why it has a better 
impact than NaB in promoting FGF21 expression since it is highly expressed in the liver. 
ATGL is a major lipase in the liver and was significantly increased by NaP, NaB, and in 
combination, which suggests these treatments may play a significant role in regulating 
lipolysis in palmitate and oleate-stimulated HepG2 cells. ATGL is a rate-limiting enzyme 
for intracellular hydrolysis of stored triglycerides and a key regulator of lipid metabolism 
[31]. ATGL may serve as a protector of hepatic inflammation through increased PPARα 
signaling, when levels of PPARα are low, the risk of developing NAFLD rises [31].  
In both models, NaP, NaB, or in combination, significantly increased PPARα and 
CPT1α mRNA expression in HepG2 cells. PPARα is a transcription factor that plays a 
critical role in hepatic lipid metabolism and regulates fatty acid synthesis and oxidation 
[52]. PPARα plays multiple roles in the liver involving FAO, anti-inflammatory, and anti-
fibrotic effects [45, 52, 53]. PPARα agonists have been considered effective treatments 
for NAFLD due to their lipid-lowering effects [54]. The treatment of NaP, NaB, or in 
combination stimulated FAO, and possibly produced anti-inflammatory and anti-fibrotic 




PPARα activates the expression of CPT1α, which leads to increased FAO [53, 55]. In the 
outer mitochondrial membrane, CPT1α is the primary regulatory enzyme involved in 
mitochondrial β-oxidation. Therefore, NaP, NaB, or in combination may play a role in 
regulating mitochondrial β-oxidation through CPT1α upregulation.  
This study found that LPS or palmitate/oleate activates inflammation in HepG2 
cells by stimulating pro-inflammatory cytokines TNF-α and IL-8. In a longitudinal analysis, 
high serum TNF-α levels in patients were associated with the development of NAFLD 
[56]. TNF-α is a major proinflammatory cytokine that causes triglyceride accumulation, 
oxidative stress, hepatocyte cell death, and hepatic steatosis [57-59]. In response to TNF-
α stimulation, IL-8 is produced [60]. IL-8 is a chemokine that acts as a chemical signal 
attracting neutrophil migration to the site of inflammation [61]. These pro-inflammatory 
cytokines are known to stimulate further liver inflammation and damage. Therefore, 
decreasing TNF-α and IL-8 is an important step in preventing the development of NAFLD. 
Our findings suggest that LPS causes more inflammation than palmitate/oleate in HepG2 
cells through the significant increase of TNF-α expression. Other studies confirm that LPS 
significantly increases TNF-α levels in HepG2 cells [25, 62, 63]. All treatments, including 
LPS and palmitate/oleate, showed no significant differences in IL-8 expression. However, 
other studies have shown that LPS and palmitate induce IL-8 in HepG2 cells [28, 59, 63, 
64]. In both models, the treatments of NaP, NaB, and in combination may exert anti-
inflammatory properties by regulating pro-inflammatory cytokines, TNF-α and IL-8, 
through HDAC inhibition since all treatments were not significantly different from the 
control. Propionate and butyrate are known to regulate cytokine expression through 




The protein expression of CPT1α increased in the palmitate/oleate model. The two 
treatments, NaP (8mM) and NaB (2mM) combined with NaP (4mM) were used based on 
the mRNA results. CPT1α catalyzes the transfer of long-chain acyl group of the acyl-CoA 
ester to carnitine, which transports fatty acids into the mitochondrial matrix for β-oxidation. 
Therefore, NaP alone or, in combination with NaB, has the potential to increase FAO by 
permitting the mitochondrial entry of FFA through the increase of CPT1α protein levels 
and mRNA expression. 
2.5. Conclusion 
NAFLD is one of the most common causes of liver dysfunction. The increase in 
circulating FFAs, palmitate and oleate, or gut-derived bacterial endotoxin, LPS, in the liver 
induces oxidative stress and pro-inflammatory cytokine production, which all contribute 
to NAFLD disease progression. In this study, we provide evidence that NaP, NaB, or in 
combination, have protective effects on palmitate/oleate- or LPS-induced cellular 
steatosis in HepG2 cells. LPS activates greater inflammation than palmitate/oleate by 
significantly increasing TNF-α expression in HepG2 cells. The treatment of NaP or NaB 
was able to promote FAO, regulate lipolysis, and reduce ROS production through the 
significant upregulation of PGC-1α, PPARα, ATGL, CPT1α, FGF21, and UCP2 mRNA 
expression in HepG2 cells. Together, NaP and NaB may produce synergistic effects by 
significantly increasing CPT1α, PPARα, and UCP2 mRNA expression in LPS-induced 
HepG2 cells and by significantly increasing CPT1α and ATGL mRNA expression in 
palmitate/oleate-induced HepG2 cells. Only NaP treatment may have the ability to 
reverse hepatic steatosis and increase whole-body energy expenditure by significantly 




The protein expression of CPT1α was increased by NaP (8mM) and the combination of 
NaB (2mM) and NaP (4mM) in the palmitate/oleate model. The study shows promising 
results for the use of SCFAs, NaP and NaB, as a potential therapy in NAFLD. We suggest 
further investigation with NaP and NaB therapy in animal and human clinical trials be 
tested.  
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CHAPTER 3. SUMMARY AND CONCLUSIONS 
 
NAFLD is the most common chronic liver disease in the United States and 
continues to rise every year. The progression of NAFLD is caused by a combination of 
the Western diet with a sedentary lifestyle, which causes the increase of FFAs, palmitate 
and oleate, or gut-derived bacterial endotoxin, LPS, to circulate inside the liver. 
Consequently, the increase of palmitate, oleate, and LPS causes oxidative stress and 
inflammation in the liver. 
Many studies have shown the benefits of SCFAs in the prevention and treatment 
of various metabolic diseases. The purpose of this dissertation was to evaluate the 
mechanisms behind NaP and NaB in FAO and explore their potential benefits in relieving 
oxidative stress and inflammation in liver cells. The mRNA expression of genes 
associated with fatty acid metabolism and the protein expression of CPT1α and pro-
inflammatory cytokines related to NAFLD using the HepG2 human liver cancer cell line 
were exposed to palmitate/oleate or LPS.  
Our results suggest that NaP, NaB, or in combination, will promote FAO, regulate 
lipolysis, and reduce ROS production while regulating pro-inflammatory cytokines in 
HepG2 cells. Together, NaP and NaB may produce synergistic effects in both models by 
effectively increasing FAO. However, only NaP treatment may have the ability to reverse 
hepatic steatosis and increase whole-body energy expenditure. This study shows the 
beneficial uses of NaP and NaB in NAFLD treatment. Therefore, future studies in NaP 
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